# Diabetes Research Hub — Monitor Report

**Generated:** 2026-06-07 (automated scheduled run)
**Scope:** Review of latest script outputs, snapshot diffs, and web check. No existing files were modified.

---

## TL;DR — What's Actionable

1. **Retatrutide Phase 3 published in *The Lancet* (Jun 6, 2026)** — new cross-domain PubMed hit [PMID 42250575], triple-agonist (GIP/GLP-1/glucagon). Highest-signal item this cycle. Worth a tracker entry and abstract pull.
2. **ADA 2026 Scientific Sessions are live now (Jun 5–8, New Orleans)** — expect a burst of new data over the next 48–72h. Re-run PubMed + trial scripts on Jun 8–9 to capture it.
3. **Gap analysis data is stale (48 days old).** `literature_gap_data.json` last refreshed Apr 20. Re-run `project1_literature_gap_analysis.py`.
4. **No clinical-trial changes today** (0 new / 0 removed / 0 status changes vs. yesterday) — trial landscape stable.

---

## File System Status

All four required input files are present and current:

| File | Last Modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-06-07 07:05 | Fresh |
| clinical_trials_latest.json | 2026-06-07 07:04 | Fresh (802 trials) |
| pubmed_recent_latest.json | 2026-06-07 07:05 | Fresh (167 papers, 30-day lookback) |
| literature_gap_report.md | 2026-06-06 08:09 | Fresh |
| **literature_gap_data.json** | **2026-04-20 15:35** | **STALE (48 days)** |

Hub monitor tracked 905 files this scan: 4 new, 29 modified, 0 removed. It flagged **686 result files older than 14 days** — most are dated daily snapshots (expected to accumulate), but the gap-analysis dataset above is the one stale file that actually feeds a Tier 1 workflow.

---

## Clinical Trial Changes

**Snapshot diff (2026-06-06 → 2026-06-07): no changes.** 0 new trials, 0 removed, 0 status changes, 0 newly posted results. Total corpus: 802 unique trials (263 RECRUITING, 124 Phase 3).

### Key Phase 3 trials currently RECRUITING from priority sponsors (Vertex, Lilly, Novo, Sana)

| NCT ID | Sponsor | Focus |
|--------|---------|-------|
| NCT06832410 | Vertex | VX-880 (zimislecel) islet cell therapy — efficacy/safety |
| NCT04786262 | Vertex | VX-880 safety/tolerability/efficacy |
| NCT07222332 | Eli Lilly | Baricitinib to preserve beta-cell function in children (T1D) |
| NCT07222137 | Eli Lilly | Baricitinib to delay Stage 3 T1D onset |
| NCT06739122 | Eli Lilly | Dulaglutide 3.0/4.5 mg, pediatric T2D |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) |
| NCT07564414 | Novo Nordisk | CagriSema dose-finding |

*(No Sana Biotechnology trials matched in the current snapshot.)*

### Recently posted results worth a look (since May 1)

- **NCT05813912** (Novo Nordisk) — weekly insulin icodec, results posted Jun 3.
- **NCT04426474** (Eli Lilly, LY3502970 / orforglipron in T2D) — results posted May 26.
- **NCT05514535** (Novo Nordisk, semaglutide + lower-dose regimen) — May 11.
- NCT04167761 (Stanford, ertugliflozin / epicardial fat) — Jun 4.

22 trials posted results since May 1; the three above touch tracked key therapies (icodec, orforglipron, semaglutide).

---

## PubMed Highlights

30-day lookback, 167 unique papers. Snapshot diff vs. yesterday: **18 new papers, 18 dropped** (rolling window).

### Cross-domain papers (highest priority — appear in ≥2 alert domains)

11 cross-domain papers in the current set. New/notable:

- **[42250575]** *Efficacy and safety of retatrutide (GIP/GLP-1/glucagon agonist) in T2D* — ***Lancet*, Jun 6.** Domains: T2D GLP-1 New + Key Therapy retatrutide. **This is the headline item.**
- **[42251179]** *Proteomic clocks + deep learning track eye aging and disease* — *NPJ Digital Medicine*, Jun 6. Domains: AI/ML + Biomarker → aligns with **Tier 1 #1 (Multi-Omics Biomarker)** and **#5 (AI/ML)**.
- **[42251203]** *Plasma small-RNA three-miRNA signature for early beta-cell dysfunction* — *Diabetologia*, Jun 6. Domains: Biomarker + Gene Therapy.
- [42198313] Diabetes & stroke review spanning orforglipron/retatrutide/CagriSema (*Pharmaceutics*).
- [42163482] Extracellular-vesicle proteins as predictive biomarkers, spanning T1D stem cell + immunotherapy + teplizumab (*Proteomics*).

### Key-therapy tracker

All 8 tracked therapies (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin) registered hits in the 30-day window. Retatrutide and teplizumab are the most active this cycle.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score 100, BRONZE validation — expert confirmation still required):

| Rank | Intersection | Joint Pubs | Tier 1 alignment |
|------|--------------|------------|------------------|
| 1 | Beta Cell Regen × Health Equity | 0 | Tier 1 #6 (epidemiology/equity) |
| 2 | Insulin Resistance × Islet Transplant | 1 | — |
| 3 | Islet Transplant × Drug Repurposing | 0 | **Tier 1 #4 (Drug Repurposing screening)** |
| 4 | Islet Transplant × Health Equity | 0 | Tier 1 #6 |
| 5 | Gene Therapy × LADA | 0 | — |

**Strongest doctrine fit:** Gap #3 (Islet Transplant × Drug Repurposing) maps directly onto Tier 1 area #4. Gaps #8 (Glucokinase × Drug Repurposing) and #12 (Drug Repurposing × Health Equity) further down the list also fit #4. These are the best candidates for an actual computational contribution rather than synthesis-only work.

*Caveat per Research Doctrine:* gap scores are keyword-based bibliometric signals, not confirmed white space. Verify each against combined-term PubMed + Cochrane/PROSPERO searches before acting.

---

## Breaking News (web check, last 7 days)

- **ADA 2026 Scientific Sessions, Jun 5–8, New Orleans** — running now, 12,000+ attendees; emphasis on beta-cell replacement, regenerative medicine, immune therapies, and AI in care. Expect a data surge; schedule a re-scan Jun 8–9. ([ADA](https://www.prnewswire.com/news-releases/the-american-diabetes-association-debuts-the-2026-scientific-sessions-driving-the-future-of-diabetes-care-302780358.html))
- **Retatrutide Phase 3 in *The Lancet* (Jun 6)** — corroborates the new PubMed cross-domain hit above.
- **Regulatory context (2026 YTD, not new this week):** oral semaglutide / Ozempic tablets approved (Feb); Awiqli once-weekly insulin icodec approved (Mar 26); first generic dapagliflozin (Apr 7); Langlara insulin glargine biosimilar (Apr 29). ([FDA generic dapagliflozin](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets), [Awiqli](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html))
- Swedish group: more reliable stem-cell-derived insulin-producing cells, reversed diabetes in mice (*Stem Cell Reports*) — preclinical; relevant to Vertex VX-880 watch. ([ScienceDaily](https://www.sciencedaily.com/releases/2026/05/260505234620.htm))

No FDA action or Phase 3 readout this week beyond the retatrutide publication rises to "must-act."

---

## Recommended Actions

1. **Add tracker entry** for retatrutide Phase 3 [PMID 42250575, *Lancet* Jun 6] under T2D Novel Therapies; pull the abstract into the paper library.
2. **Re-run `project1_literature_gap_analysis.py`** — `literature_gap_data.json` is 48 days old and feeds Tier 1 gap work.
3. **Schedule a Jun 8–9 re-scan** of `baseline_pubmed_alerts.py` and `baseline_clinical_trials.py` to capture ADA 2026 output.
4. **Review cross-domain papers** [42251179] (AI/ML × Biomarker) and [42251203] (Biomarker × Gene Therapy) — both fit Tier 1 multi-omics/biomarker focus.
5. **Consider scoping** the Islet Transplant × Drug Repurposing gap (Gap #3) as the next computational project — strongest Tier 1 #4 fit among current top gaps.

---
*Automated review run — files read, not modified. Evidence levels noted per Research Doctrine; gap classifications remain BRONZE pending expert validation.*
